Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology

We previously performed a comparative assessment of tissue-level vascular physiological parameters in mice and rats, two of the most commonly utilized species in translational drug development. The present work extends this effort to non-human primates by measuring tissue- and organ-level vascular volumes (Vv), interstitial volumes (Vi), and blood flow rates (Q) in cynomolgus monkeys. These measurements were accomplished by red blood cell labeling, extracellular marker infusion, and rubidium chloride bolus distribution, respectively, the same methods used in previous rodent measurements. In addition, whole-body blood volumes (BV) were determined across species. The results demonstrate that Vv, Vi, and Q, measured using our methods scale approximately by body weight across mouse, rat, and monkey in the tissues considered here, where allometric analysis allowed extrapolation to human parameters. Significant differences were observed between the values determined in this study and those reported in the literature, including Vv in muscle, brain, and skin and Q in muscle, adipose, heart, thymus, and spleen. The impact of these differences for selected tissues was evaluated via sensitivity analysis using a physiologically based pharmacokinetic model. The blood-brain barrier in monkeys was shown to be more impervious to an infused radioactive tracer, indium-111-pentetate, than in mice or rats. The body weight-normalized total BV measured in monkey agreed well with previously measured value in rats but was lower than that in mice. These findings have important implications for the common practice of scaling physiological parameters from rodents to primates in translational pharmacology.

[1]  Neil D. Theise,et al.  Structure and Distribution of an Unrecognized Interstitium in Human Tissues , 2018, Scientific Reports.

[2]  B. Krippendorff,et al.  Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches , 2017, The Journal of physiology.

[3]  K. Scearce-Levie,et al.  Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates , 2017, British journal of pharmacology.

[4]  F. Cordero,et al.  Biologic Data of Cynomolgus Monkeys Maintained under Laboratory Conditions , 2016, PloS one.

[5]  H. Koeppen,et al.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor , 2016, mAbs.

[6]  M. Brug,et al.  Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies , 2015, Neuron.

[7]  A. Kjær,et al.  Quantitative myocardial blood flow with Rubidium-82 PET: a clinical perspective. , 2015, American journal of nuclear medicine and molecular imaging.

[8]  William J. Jusko,et al.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model , 2015, Pharmaceutical Research.

[9]  K. Scearce-Levie,et al.  Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates , 2014, Science Translational Medicine.

[10]  J. Riviere,et al.  The application of allometric scaling principles to predict pharmacokinetic parameters across species , 2014, Expert opinion on drug metabolism & toxicology.

[11]  L. Khawli,et al.  Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. , 2014, Molecular pharmaceutics.

[12]  H. Klein,et al.  Mollison's Blood Transfusion in Clinical Medicine , 2014 .

[13]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[14]  L. Khawli,et al.  Vascular physiology and protein disposition in a preclinical model of neurodegeneration. , 2013, Molecular pharmaceutics.

[15]  L. Khawli,et al.  Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody–Drug Conjugate , 2012, The Journal of Nuclear Medicine.

[16]  F. Theil,et al.  Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations , 2012, The AAPS Journal.

[17]  Andreas A Linninger,et al.  Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. , 2012, Journal of pharmaceutical sciences.

[18]  M. Sliwkowski,et al.  Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model , 2012, Molecular Cancer Therapeutics.

[19]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  Maria I. Zavodszky,et al.  BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[22]  F. Theil,et al.  Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow , 2011, PloS one.

[23]  Anna M. Wu,et al.  Erratum to: A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[24]  F. Theil,et al.  Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. , 2010, Molecular pharmaceutics.

[25]  Joseph P Balthasar,et al.  Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. , 2010, Journal of pharmaceutical sciences.

[26]  Elaina M Kenyon,et al.  A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  W. Hayton,et al.  Allometric scaling of xenobiotic clearance: Uncertainty versus universality , 2008, AAPS PharmSci.

[28]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[29]  Hung Q. Dam,et al.  Blood Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a Classic Study* , 2007, Journal of Nuclear Medicine Technology.

[30]  Choong-Yong Kim,et al.  Indirect indicator of transport stress in hematological values in newly acquired cynomolgus monkeys , 2005, Journal of medical primatology.

[31]  W. Geldenhuys,et al.  Brain Uptake Kinetics of Nicotine and Cotinine after Chronic Nicotine Exposure , 2005, Journal of Pharmacology and Experimental Therapeutics.

[32]  J. Rendell,et al.  Potassium transport in Langendorff‐perfused mouse hearts assessed by 87Rb NMR spectroscopy , 2005, Magnetic resonance in medicine.

[33]  P. Sinko,et al.  P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[34]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  Anna M. Wu,et al.  A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[36]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[37]  J. Mordenti,et al.  Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins , 1991, Pharmaceutical Research.

[38]  V. R. McCready,et al.  99mTc-HMPAO as a tumour blood flow agent , 2004, European Journal of Nuclear Medicine.

[39]  W. Bachmann,et al.  In vivo/in vitro labeling of red blood cells with 99mTc , 2004, European Journal of Nuclear Medicine.

[40]  D. Levitt,et al.  The pharmacokinetics of the interstitial space in humans , 2003, BMC clinical pharmacology.

[41]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[42]  S. Lindstedt,et al.  Use of allometry in predicting anatomical and physiological parameters of mammals , 2002, Laboratory animals.

[43]  Robin Hull,et al.  A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.

[44]  D. Goldenberg,et al.  Regulation of tumour drug delivery by blood flow chronobiology. , 2000, European journal of cancer.

[45]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[46]  A. Tefferi,et al.  Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. , 1996, Blood cells, molecules & diseases.

[47]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[48]  R K Jain,et al.  Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.

[49]  R. Reed,et al.  Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. , 1993, Physiological reviews.

[50]  R. Tompkins,et al.  A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. , 1992, Cancer research.

[51]  S. Khor,et al.  Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[52]  R. Youle,et al.  Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. , 1990, Cancer research.

[53]  I. A. Watson,et al.  Quantitative in vivo measurements of tumor perfusion using rubidium-81 and positron emission tomography. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  R. Vessella,et al.  Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. , 1988, Cancer research.

[55]  N. Mullani,et al.  Skeletal muscle blood flow in vivo: detection with rubidium-82 and effects of glucose, insulin, and exercise. , 1987, Journal of Nuclear Medicine.

[56]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[57]  S. R. Gautam,et al.  Determination of gallium concentration in "blood-free" tissues using a radiolabeled blood marker. , 1985, Journal of pharmaceutical sciences.

[58]  S. Shah,et al.  Vascular volume and permeability of human and murine tumors grown in athymic mice. , 1985, Cancer letters.

[59]  L. Smith,et al.  Cardiac output distribution and regional blood flow during hypocarbia in monkeys. , 1985, Journal of applied physiology.

[60]  M D Blaufox,et al.  Blood volume in the rat. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J Marshall,et al.  Quantitative Measurement of Blood—Brain Barrier Permeability Using Rubidium-82 and Positron Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  S. W. O'Connor,et al.  Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. , 1984, Cancer research.

[63]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[64]  Madan M. Rehani,et al.  Site of Tc-99m binding to the red blood cell: concise communication. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  D G Pavel,et al.  In vivo labeling of red blood cells with 99mTc: a new approach to blood pool visualization. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  J. Vácha Blood volume in inbred strain BALB/c, CBA/J and C57BL/10 mice determined by means of 59Fe-labelled red cells and 59Fe bound to transferrin. , 1975, Physiologia Bohemoslovaca.

[67]  J. Fowler,et al.  The measurement of blood perfusion in experimental tumors by uptake of 86Rb. , 1974, Cancer research.

[68]  T. McMahon,et al.  Size and Shape in Biology , 1973, Science.

[69]  J. Sharp,et al.  Blood volume determination in the mouse , 1973, The Journal of physiology.

[70]  G. Denardo,et al.  Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. , 1972, Cancer research.

[71]  N. Hollenberg,et al.  Cardiac output distribution in the rat: comparison of rubidium and microsphere methods. , 1971, The American journal of physiology.

[72]  R. F. Johnson,et al.  The significance of the total-body hematocrit in measurements of blood compartments. , 1971, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  S. Ayres,et al.  Peripheral Vascular Volumes and Whole Body Hematocrit During Human Heart Lung Bypass , 1970, Circulation.

[74]  K. Melmon,et al.  Normal distribution of cardiac output in the unanesthetized, restrined rhesus monkey. , 1968, Journal of applied physiology.

[75]  E. Malone,et al.  Determination of Total Blood Volume from Measurements of Total Red Blood Cell Mass and Plasma Volume, using Simultaneously Injected Isotopes , 1964, Nature.

[76]  P. Gullino,et al.  Studies on the exchange of fluids between host and tumor. III. Regulation of blood flow in hepatomas and other rat tumors. , 1962, Journal of the National Cancer Institute.

[77]  W. Dameshek,et al.  The body hematocrit/venous hematocrit ratio and the "splenic reservoir". , 1961, Blood.

[78]  L. Sapirstein,et al.  Regional blood flow by fractional distribution of indicators. , 1958, The American journal of physiology.

[79]  H. Vetter,et al.  The body/venous hematocrit ratio: its constancy over a wide hematocrit range. , 1953, The Journal of clinical investigation.

[80]  E. Adolph,et al.  Quantitative Relations in the Physiological Constitutions of Mammals. , 1949, Science.